Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Since 2010, several treatment options have been available for men with metastatic castration-resistant prostate cancer (mCRPC), including immunotherapeutic agents, although the clinical benefit of these agents remains inconclusive in unselected mCRPC patients. In recent years, however, immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz de Porras, Vicenç, Pardo, Juan Carlos, Notario, Lucia, Etxaniz, Olatz, Font, Albert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124759/
https://www.ncbi.nlm.nih.gov/pubmed/33946818
http://dx.doi.org/10.3390/ijms22094712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124759/
https://www.ncbi.nlm.nih.gov/pubmed/33946818
http://dx.doi.org/10.3390/ijms22094712

Ejemplares similares